LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB: HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, will be exhibiting at the annual meeting of the International Society of Stem Cell Research (ISSCR) June 14-17 in Boston, MA. The conference celebrates its 15th year by bringing together over 3,000 attendees from around the world to discuss recent innovation in stem cell research and regenerative medicine. This year’s conference program emphasizes translation of stem cell research to the clinic, with plenary sessions on ethical implications of stem cell therapy as well as preparation and safety of stem cells for the clinical setting.
“Our customers are on the cutting edge of developing new cell-based therapies using immune stem cells collected and processed in our laboratory,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “We are attending ISSCR to meet with customers and to hear about the latest developments and needs in stem cell research so we may better serve the scientists in this exciting and rapidly evolving field.”
Visit HemaCare and meet several members of our sales, marketing, and executive team at the Boston Convention and Exhibition Center, Booth #906, or view our product story at www.hemacare.com.
About HemaCare
HemaCare Corporation is a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy. Our expertise has evolved through 39 years in the business of blood collection, processing and storage. In addition, we have established a robust donor recruitment and management system which supports an extensive registry of well-characterized repeat donors. HemaCare’s controlled procedures ensure a readily available inventory of high-quality, consistent and selectable primary human cells and biological products for advanced biomedical research. Our customers are engaged in basic research and development of clinical therapies that are designed to manipulate the immune system for treatment and cure of cancer, degenerative diseases and immune and genetic disorders. HemaCare’s products and services address several key markets, including immune therapy research, cell manufacturing for clinical therapy, and clinical laboratory instrument development. We specialize in custom cell collections for customers who may require donors with specific attributes (phenotypic or disease state, for example), or sub-sets of immune cells that can be selected in our laboratory using the latest technology. HemaCare’s products and services address all stages of cell therapy development, from basic biological research in academic institutions to pharmaceutical cell development in large drug companies. For more information, please visit www.hemacare.com.
